NKGen Starts Phase 1/2a Trial with Autologous NK Cell Product for Alzheimer’s

 NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1 dose-escalation safety trial.

SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD.

Initial patient in this Phase 1/2a trial received 6 billion cells, 50% more than the maximum dosing from the Phase 1 trial.

https://www.globenewswire.com/news-release/2023/12/28/2801852/0/en/NKGen-Biotech-Inc-Announces-Dosing-of-First-Patient-in-its-Phase-1-2a-Trial-with-Autologous-NK-Cell-Product-SNK01-for-the-Treatment-of-Moderate-Alzheimer-s-Disease.html